The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include phase 3 CORALreef AddOn data on the investigational oral PCSK9 inhibitor enlicitide versus other non-statin therapies for LDL-C lowering, an FDA label update removing the age restriction for epinephrine nasal spray (neffy), phase 2 data for Sanofi's bispecific TSLP/IL-13 inhibitor lunsekimig across asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis, new joint ASH/ISTH recommendations on anticoagulant prophylaxis in pediatric patients at risk for venous thromboembolism, and positive phase 3 topline results for subcutaneously administered teprotumumab-trbw (Tepezza) via on-body injector in thyroid eye disease.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of April 5, 2026 — let's jump in!

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

The investigational oral PCSK9 inhibitor enlicitide achieved a mean LDL-C reduction of 64.6% from baseline versus 6.3%, 27.8%, and 36.5% for bempedoic acid, ezetimibe, and bempedoic acid plus ezetimibe, respectively, in the phase 3 CORALreef AddOn trial in patients with ASCVD risk on background statin therapy (all P <.001). The findings, presented at ACC Scientific Sessions 2026 in New Orleans, position enlicitide as a potentially potent add-on option for patients who cannot achieve LDL-C targets on statins alone, with an outcome study ongoing.

FDA Removes Age Restriction for Epinephrine Nasal Spray, With Nicole Chase, MD

The FDA eliminated the minimum age requirement for 1 mg epinephrine nasal spray (neffy), shifting prescribing guidance to a weight-based threshold of ≥33 pounds and expanding access to a broader pediatric population. The label update, announced March 27, also clarifies dosing, storage, and administration technique, including guidance that patients avoid sniffing during delivery to minimize adverse effects.

Lunsekimig Meets End Points in Asthma and CRSwNP, Misses in Atopic Dermatitis

Sanofi's lunsekimig, a bispecific agent targeting both TSLP and IL-13, met its primary and key secondary endpoints in the phase 2b AIRCULES trial in moderate-to-severe asthma and in the phase 2a DUET trial in chronic rhinosinusitis with nasal polyps, though it did not meet its primary endpoint in the exploratory phase 2b VELVET study in atopic dermatitis. Full numeric data from all 3 studies have not yet been disclosed; Sanofi has characterized respiratory indications as the primary development focus and has phase 3 COPD trials underway.

12 New Recommendations for Anticoagulant Prophylaxis in Pediatric Patients at Risk for Venous Thromboembolism

A joint ASH and ISTH expert panel published 12 evidence-based recommendations in Blood Advances on April 8 to guide anticoagulant prophylaxis decisions in pediatric patients at risk for VTE, addressing a gap previously filled by adult-derived data. Conditional recommendations include suggesting no prophylaxis in pediatric patients with solid cancer, trauma, or critical illness, and suggesting prophylaxis for those with antiphospholipid antibody syndrome or on long-term total parenteral nutrition, among other subgroup-specific guidance.

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

A phase 3 trial of subcutaneously administered teprotumumab-trbw (Tepezza) via on-body injector met its primary endpoint in moderate-to-severe active thyroid eye disease, with 76.7% of patients achieving a ≥2 mm proptosis reduction at week 24 versus 19.6% on placebo (P <.0001), and a mean proptosis reduction of 3.17 mm versus 0.8 mm. The results, announced by Amgen on April 6, extend the established IV efficacy profile of Tepezza to a subcutaneous delivery format that may improve accessibility for a broader patient population.